MEDIROM Healthcare Technologies
MRM
1 hedge funds and large institutions have $8.74K invested in MEDIROM Healthcare Technologies in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
33% less capital invested
Capital invested by funds: $13K → $8.74K (-$4.25K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.02K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $8.74K | -$1.02K | -173 | -8% |
|
MRM Hedge Fund Activity: Q4 2022 in Review
1 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in MEDIROM Healthcare Technologies (MRM) for Q4 2022, worth a combined $8.74K — down 33% from $13K a quarter earlier.
Fund positioning in MRM was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $1.02K.
- 1 institutional investor held MEDIROM Healthcare Technologies (MRM) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $8.74K of MEDIROM Healthcare Technologies stock for Q4 2022, down 33% quarter-over-quarter.
- 0 funds opened new MEDIROM Healthcare Technologies positions in Q4 2022 and 0 closed out.
- The largest MEDIROM Healthcare Technologies seller in Q4 2022 was UBS Group, an estimated $1.02K sold.
Based on aggregated 13F filings for Q4 2022.